



# Supplementary Material: Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey


Anup Kasi, Efrat Dotan, Graham M. Poage, Aurelie Catteau, Dewi Vernerey, Manju George and Afsaneh Barzi



**Figure S1.** Percentage of Participant Recommendations for Adjuvant Chemotherapy by Associated Patient Prognostic Risk Factors (Pre-test).



**Figure S2.** Impact of Immunoscore-Low Classification on Adjuvant Chemotherapy Recommendations in Cases with Prognostic Risk Factors. \* No cases were represented with these clinicopathologic features.



**Figure S3.** Hierarchical Clustering of Participant Recommendations for Adjuvant Chemotherapy and Associated Demographic Factors.

**Table S1.** Patient and Disease Profiles.

Characteristic	Value
Age	
Median (range), yr	63.5 (48-78)
>70 yr, <i>n</i> (%)	4 (40)
Comorbidities, <i>n</i> (%)	2 (20)
Tumor stage, <i>n</i> (%)	
T3	7 (70)
T4	3 (30)
Lymphatic, perineural, or perivascular invasion, <i>n</i> (%)	3 (30)
Inadequate lymph node harvest, <i>n</i> (%)	1 (10)
Bowel obstruction, <i>n</i> (%)	0
Perforation, <i>n</i> (%)	0
Poorly differentiated histology, <i>n</i> (%)	7 (70)
MSI-H/dMMR, <i>n</i> (%)	5 (50)
Immunoscore, <i>n</i> (%)	
Low	3 (30)
High	7 (70)

MSI/dMMR, microsatellite instability/deficient mismatch repair.

**Table S2.** Changes in Medical Oncologist Recommendations Regarding Adjuvant Chemotherapy and Surveillance Intensity Post-Immunoscore by Oncologist and Case.

Partici- pant	Case 1 (IS-High)	Case 2 (IS-High)	Case 3 (IS-High)	Case 4 (IS-Low)	Case 5 (IS-High)	Case 6 (IS-Low)	Case 7 (IS-High)	Case 8 (IS-Low)	Case 9 (IS-High)	Case 10 (IS-High)	Any Case
1	AC	AC	--	--	--	AC	AC	--	--	--	Yes
2	AC, S	--	--	S	AC, S	AC	AC	S	AC, S	AC	Yes
3	S	--	--	S	--	S	--	AC, S	--	--	Yes
4	AC, S	AC, S	AC, S	AC, S	AC, S	AC, S	S	S	AC, S	S	Yes
5	AC	--	AC, S	AC	AC	S	AC, S	S	--	S	Yes
6	AC, S	AC, S	S	--	S	AC, S	AC, S	--	S	AC, S	Yes
7	--	S	AC	S	S	S	--	S	--	S	Yes
8	AC	AC	--	AC	--	AC, S	AC	AC	--	--	Yes
9	--	--	--	--	--	--	--	--	--	--	No
10	--	--	--	AC	--	AC	--	AC	--	--	Yes
11	AC	--	--	S	--	S	--	AC, S	--	S	Yes
12	AC, S	S	AC, S	AC, S	AC	AC, S	S	AC, S	AC, S	AC, S	Yes
13	--	--	--	--	--	S	--	AC	S	--	Yes
14	AC, S	--	S	--	AC, S	--	--	AC, S	AC, S	S	Yes
15	--	AC	AC	--	--	AC	AC	--	--	AC	Yes
16	--	--	--	--	--	S	--	S	--	--	Yes
17	AC, S	AC, S	--	S	--	S	AC	--	--	--	Yes
18	S	S	S	--	S	--	--	--	--	AC	Yes
19	--	AC	AC	AC	--	S	AC	--	--	S	Yes
20	S	S	S	--	S	AC	S	AC	AC, S	S	Yes
21	S	S	S	--	S	AC	S	AC	--	--	Yes
22	--	--	--	AC	--	--	--	--	--	--	Yes
23	AC, S	AC, S	AC, S	--	AC, S	AC, S	AC	--	AC, S	AC, S	Yes
24	S	--	S	--	S	S	S	--	--	S	Yes
25	AC	--	--	--	AC	AC	--	--	AC	--	Yes
Any Par- ticipant	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	

AC, change in recommendation for adjuvant chemotherapy; S, change in recommendation for surveillance. --, no change in clinical recommendations